Facing $50B Trial, Drugmakers Minimize Roles In Opioid Sales

Allergan PLC on Tuesday downplayed its Golden State opioid sales, echoing the strategies of fellow drugmaker defendants from the day before in a closely watched trial where major California counties are...

Already a subscriber? Click here to view full article